5 min read · Research education
What Is CJC-1295 + Ipamorelin? Research Overview
CJC-1295 and Ipamorelin are frequently studied together because they act on two different parts of the growth-hormone pathway. Here's why.
CJC-1295 + Ipamorelin is a research peptide combination pairing two compounds that act on complementary points of the growth-hormone signaling pathway. It is studied in research on growth-hormone dynamics in controlled models.
Two complementary mechanisms
CJC-1295 is a long-acting analog of growth hormone–releasing hormone (GHRH), providing extended GHRH-pathway activity. Ipamorelin is a selective ghrelin-receptor agonist (a growth-hormone secretagogue). Because they engage different receptors that both feed into growth-hormone signaling, researchers study the pair to investigate combined effects in vitro.
Research context
This combination is studied for growth-hormone signaling dynamics in laboratory models. It is supplied strictly for research use only and is not for human consumption.
Frequently asked questions
Why are CJC-1295 and Ipamorelin combined?
They act on two different receptors in the growth-hormone pathway — GHRH and the ghrelin receptor — so researchers study them together to investigate complementary signaling.
Is this combination for human use?
No. It is supplied for laboratory research use only.
Related research peptides
This article is provided for educational and research-context purposes only and does not constitute medical, dosing, or human-use guidance. All products referenced are sold by Peptide Depot strictly for laboratory research use only and are not for human or veterinary consumption.